WALVAX(300142)2024-04-24 12:58Financial Performance - Revenue for the first quarter of 2024 was RMB 599.75 million, a decrease of 28.02% compared to the same period last year[4] - Net profit attributable to shareholders of the listed company was RMB 14.13 million, a significant decrease of 91.79% year-on-year[4] - Revenue for the first quarter of 2024 was 599.75 million yuan, a decrease of 28.0% compared to 833.27 million yuan in the same period last year[21] - Operating profit for the first quarter of 2024 was 59.65 million yuan, a significant decrease of 72.2% compared to 214.48 million yuan in the same period last year[21] - Net profit attributable to the parent company's owners was 14.13 million yuan, a sharp decline of 91.8% compared to 171.99 million yuan in the same period last year[21] - Sales revenue from goods and services was 595.88 million yuan, a decrease of 36.6% compared to 939.34 million yuan in the same period last year[23] - Basic earnings per share for the first quarter of 2024 was 0.0088 yuan, a significant decrease of 91.8% compared to 0.1074 yuan in the same period last year[22] Cash Flow - Net cash flow from operating activities was negative RMB 75.59 million, a decrease of 137.20% compared to the same period last year[4] - Cash flow from operating activities was 631.85 million yuan, a decrease of 38.9% compared to 1.03 billion yuan in the same period last year[23] - Operating cash flow for the first quarter of 2024 was -75.59 million yuan, compared to 203.20 million yuan in the same period last year[24] - Investment cash flow for the first quarter of 2024 was -162.35 million yuan, compared to -249.33 million yuan in the same period last year[24] - Financing cash flow for the first quarter of 2024 was -14.22 million yuan, compared to 6.04 million yuan in the same period last year[24] - Net cash and cash equivalents decreased by 252.07 million yuan in the first quarter of 2024, compared to a decrease of 40.41 million yuan in the same period last year[24] - The company's cash and cash equivalents balance at the end of the first quarter of 2024 was 4.10 billion yuan, compared to 3.75 billion yuan at the end of the same period last year[24] - Taxes paid in the first quarter of 2024 were 46.68 million yuan, compared to 54.00 million yuan in the same period last year[24] - Cash paid for other operating activities in the first quarter of 2024 was 30.68 million yuan, compared to 1.52 million yuan in the same period last year[24] - Cash paid for the construction of fixed assets, intangible assets, and other long-term assets in the first quarter of 2024 was 153.55 million yuan, compared to 249.53 million yuan in the same period last year[24] - Cash received from financing activities in the first quarter of 2024 was 183.94 thousand yuan, compared to 118.45 million yuan in the same period last year[24] Assets and Liabilities - Total assets at the end of the reporting period were RMB 15.39 billion, a slight decrease of 1.30% compared to the end of the previous year[4] - Total assets decreased from RMB 155.89 billion to RMB 153.87 billion, a decrease of 1.3%[19][20] - Current assets decreased from RMB 87.33 billion to RMB 84.96 billion, a decrease of 2.7%[19] - Accounts receivable decreased from RMB 3.10 billion to RMB 3.06 billion, a decrease of 1.3%[19] - Inventory increased from RMB 1.03 billion to RMB 1.10 billion, an increase of 6.4%[19] - Total liabilities decreased from RMB 41.94 billion to RMB 39.53 billion, a decrease of 5.7%[20] - Current liabilities decreased from RMB 32.04 billion to RMB 29.78 billion, a decrease of 7.1%[20] - Long-term liabilities decreased from RMB 9.90 billion to RMB 9.76 billion, a decrease of 1.4%[20] - Total equity increased from RMB 113.95 billion to RMB 114.34 billion, an increase of 0.3%[20] - Net profit attributable to parent company increased from RMB 2.90 billion to RMB 2.92 billion, an increase of 0.7%[20] - Minority interest increased from RMB 2.05 billion to RMB 2.07 billion, an increase of 1.2%[20] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 121,706[10] - Liu Junhui holds 3.37% of the shares, totaling 54,161,648 shares[10] - Hong Kong Securities Clearing Company Limited holds 3.09% of the shares, totaling 49,683,636 shares[10] - China Industrial and Commercial Bank - E Fund ChiNext ETF holds 2.11% of the shares, totaling 33,897,349 shares[10] - China Bank - China Merchants Securities Biopharmaceutical Index Fund holds 1.92% of the shares, totaling 30,814,551 shares[10] - Yang Geng holds 1.89% of the shares, totaling 30,305,900 shares, with 13,000,000 shares pledged[10] - Li Yunchun holds 1.69% of the shares, totaling 27,150,181 shares, with 20,362,636 shares under restricted sale[10] - Yuxi High-tech Management Group holds 1.50% of the shares, totaling 24,038,398 shares[10] - Chengdu Xiyun Enterprise Management Partnership holds 1.47% of the shares, totaling 23,656,807 shares[10] - Huang Jing holds 1.47% of the shares, totaling 23,632,589 shares[10] Share Repurchase and Issuance - The company completed the share repurchase plan, repurchasing 2,000,000 shares, accounting for 0.12% of the total shares, with a total repurchase amount of RMB 72,197,766.44[15] - The company changed the purpose of the repurchased shares from "employee stock ownership plan or equity incentive plan" to "cancellation and reduction of registered capital," involving 2,000,000 shares[15] - The company terminated the issuance of convertible bonds to unspecified objects, with a planned issuance amount not exceeding RMB 1,235,298,400[16] - The company proposed a simplified procedure for issuing shares to specific objects, with a financing limit not exceeding RMB 300 million and not exceeding 20% of the company's net assets at the end of the previous year[17] - The total number of shares repurchased and held in the company's repurchase account is 7,999,943 shares, including 5,999,943 shares repurchased in 2022[16] Government Subsidies and Fair Value Changes - Government subsidies received during the reporting period amounted to RMB 17.57 million[5] - Fair value changes in financial assets resulted in a loss of RMB 84.82 million, primarily due to the decline in the stock price of Cayman Sinopharm Co., Ltd.[5] Employee Compensation and Taxes - Employee compensation payable decreased by 76.92% to RMB 269.03 million, mainly due to the payment of year-end bonuses accrued at the end of the previous year[6] - Taxes payable decreased by 43.47% to RMB 241.93 million, primarily due to reduced vaccine product sales and corresponding profit decline[6] Investment and Financing Activities - Investment activities generated a net cash outflow of RMB 162.35 million, a decrease of 34.89% compared to the same period last year[9] - Financing activities resulted in a net cash outflow of RMB 142.24 million, a significant decrease of 335.46% year-on-year[9] R&D Expenses - R&D expenses decreased by 51.4% to 87.02 million yuan in the first quarter of 2024, compared to 178.91 million yuan in the same period last year[21] Audit Status - The company's first quarter report for 2024 was not audited[24]